Cholera vaccine inactivated oral - Valneva

Drug Profile

Cholera vaccine inactivated oral - Valneva

Alternative Names: Vibrio cholerae and enterotoxigenic Escherichia coli vaccine - Crucell/sanofi-aventis; Dukoral; SBL Cholera Vaccine; WC/rBS; whole cell/recombinant B subunit cholera vaccine

Latest Information Update: 29 Jan 2016

Price : $50

At a glance

  • Originator SBL Vaccin AB
  • Developer Crucell; Valneva
  • Class Cholera vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cholera; Escherichia coli infections

Most Recent Events

  • 26 Jan 2016 IC 51 sub-licensed to GlaxoSmithKline in Germany
  • 23 Jul 2015 Inactivated oral cholera vaccine (Dukoral®) licensed to PaxVax for commercialisation in Italy, Spain and Portugal
  • 23 Nov 2006 SBL Vaccin AB has been acquired by Crucell
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top